1 herefore, it has been proposed for use as an antifibrinolytic agent.

2 n those who received aminocaproic acid or no antifibrinolytic agent.

3                                Because the 2 antifibrinolytic agents appear to have similar efficacie

4 ared with the use of aminocaproic acid or no antifibrinolytic agent, aprotinin use was also associate

5 ich are representative of a class of in vivo antifibrinolytic agents, have been determined at 2.1 ang

6 nephrotoxic insults are presented, including antifibrinolytic agents, obstructive jaundice, prostagla

7 teric inhibition of plasmin could led to new antifibrinolytic agent(s) that may exhibit better effica

8 d to delay clot lysis by enhancing a natural antifibrinolytic agent, thrombin-activatable fibrinolysi

9  or tranexamic acid, which have been used as antifibrinolytic agents to prevent blood loss during maj

10                               The use of the antifibrinolytic agents urokinase and recombinant tissue

11                                          All antifibrinolytic agents were effective in reducing blood